The Number 1 Reason Options Traders Lose Money (and How You Can Avoid the Trap)
By Don Fishback
I’ve good news and bad news.
The good news is that options trading has gone mainstream. Option volume is skyrocketing, and option liquidity is plentiful.
The bad news is that retail options traders are getting clobbered. Loss estimates are in the billions.
Those gargantuan losses prompted investigators to pore through the data to see if there was a common reason for so many mom and pop traders losing so much money.
What they found surprised them, because it’s something I have preached for years. And now, in this revealing video, you can learn the #1 wealth-depleting mistake retail options traders make.
More important, I provide you with a simple solution that makes so much sense, you’ll instantly be wanting to put the power of probability on your side.
But not just any probability. We’re talking about the most accurate probability tailored for every stock, every market, and every time period.
At the moment, pharmaceutical companies are applying artificial intelligence (AI) and machine learning (ML) to drug development. With those tools, they’re creating new drugs for a range of ailments, and potential multi-billion-dollar opportunities, says Morgan Stanley.
That’s because – with AI – success rates in drug trials are higher.
Right now, new drug development has a ridiculous fail rate of 90% for companies.
However, with artificial intelligence, the rate of failure could drop, and the design of new drugs could become far easier. In fact, according to Pfizer, AI could assist pharma companies in getting medicines to market faster. AI today not only does flashy gene-sequencing work, it’s being trained to predict drug efficacy and side effects, and to manage the vast amounts of documents and data that support any pharmaceutical product.
We can trade that potential with companies, such as:
Lantern Pharma Inc. (LTRN)
With a market cap of just over $50 million, be cautious with Lantern Pharma (LTRN). But also realize it could potentially be a game-changer in the fight against cancer with AI. With the help of machine learning, AI, and advanced genomics, its platform can scan billions of data points to help identity compounds that could help cancer patients.
With early-stage discovery and development, the traditional approach can take three to five years, and between $10 million and $50 million. With Lantern, the process can be as low as two years, with $1 million to $5 million in costs. Even better, with the assistance of its AI Platform, RADR, the company created LP-184 for solid tumors, and just received US FDA clearance to begin testing in Phase 1 trials.
Futures contracts are standardized. This means they have a predetermined quantity, quality, specified time and location for delivery. Futures contracts are also known as exchange traded obligations. This means that they are transferable legal agreements.
The futures contract conveys an agreement to buy or sell a specific amount of a commodity (like wheat or crude oil) at a particular price at a specific time in the future. A futures contract obligates the buyer to purchase the underlying (cash market) commodity, and the seller to sell it.
Third Party Guarantee
Another, if not the most important benefit of futures trading, is the third party performance guarantee. Unlike forward contracts (an unregulated form of futures contract) which have no third party involvement, should one party (buyer or seller) default on his/her obligation, payment is still guaranteed to the other party.
Elite Wall Street trader, Joe Duffy, is allowing a limited group of future-elite investors into his masterful daily trades at thousands of dollars less than what others charge.
When you join today for $1, the first month you'll receive:
Joe Duffy’s daily video newsletter with updates on what's happening in the markets that very day. Rather than watch talking heads for hours on cable, I'll get you up to speed in minutes.
You get weekend updates where I delve more into 'bigger picture' looks at the marketplace. Videos are illustrative, instructive, concise, and un-hedged. No double talk here.
The first profit opportunity we will review is in FTI, or TechnipFMC plc. FTI is a leading manufacturer and supplier of products, services, and fully integrated technology solutions for the energy industry.
The monthly chart shows that FTI closed above the moving average line every month since July 2022. That’s a long, strong, steady bull trend!
The daily chart shows that FTI has been moving steadily higher since June 1st. The next target is 25.
We recommend buying FTI stock at the current price level. The FTI dividend yield is 1.05%.
PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading.
1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis.
2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services.
3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber.
4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more.
5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities.
6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown.
7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses.
8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.
If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription TradeWins Publishing, 528 North Country Rd., St. James, NY 11780
0 Response to "Top Ways to Trade the AI Boom in Biotech"
Post a Comment